Solomon Moshkevich Sells 3,000 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 3,000 shares of Natera stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $202.30, for a total value of $606,900.00. Following the sale, the insider directly owned 147,882 shares of the company’s stock, valued at $29,916,528.60. This trade represents a 1.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Solomon Moshkevich also recently made the following trade(s):

• On Tuesday, March 10th, Solomon Moshkevich sold 915 shares of Natera stock. The stock was sold at an average price of $204.13, for a total value of $186,778.95.
• On Monday, March 2nd, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $199.85, for a total value of $599,550.00.
• On Tuesday, February 3rd, Solomon Moshkevich sold 1,639 shares of Natera stock. The stock was sold at an average price of $230.77, for a total value of $378,232.03.
• On Monday, February 2nd, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $231.44, for a total value of $694,320.00.
• On Wednesday, January 28th, Solomon Moshkevich sold 1,200 shares of Natera stock. The shares were sold at an average price of $237.66, for a total value of $285,192.00.
• On Tuesday, January 27th, Solomon Moshkevich sold 1,013 shares of Natera stock. The shares were sold at an average price of $240.53, for a total transaction of $243,656.89.
• On Wednesday, January 21st, Solomon Moshkevich sold 293 shares of Natera stock. The stock was sold at an average price of $235.00, for a total transaction of $68,855.00.
• On Tuesday, January 20th, Solomon Moshkevich sold 23,205 shares of Natera stock. The stock was sold at an average price of $234.74, for a total transaction of $5,447,141.70.

Natera Stock Performance

Shares of NASDAQ:NTRA opened at $207.98 on Friday. The firm has a 50 day simple moving average of $207.26 and a 200-day simple moving average of $209.40. Natera, Inc. has a twelve month low of $125.38 and a twelve month high of $256.36. The company has a market capitalization of $29.48 billion, a PE ratio of -135.93 and a beta of 1.68.

Natera (NASDAQ:NTRA) last posted its earnings results on Thursday, February 26th. The medical research company reported $0.35 EPS for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.81. Natera had a negative net margin of 9.03% and a negative return on equity of 15.28%. The firm had revenue of $665.50 million for the quarter, compared to the consensus estimate of $600.68 million. During the same period last year, the firm posted ($0.41) EPS. As a group, equities research analysts predict that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Robert W. Baird lifted their target price on Natera from $239.00 to $257.00 and gave the stock an “outperform” rating in a research report on Friday, February 27th. Canaccord Genuity Group reissued a “buy” rating on shares of Natera in a research report on Monday, January 12th. JPMorgan Chase & Co. raised their price target on Natera from $250.00 to $260.00 and gave the stock an “overweight” rating in a research note on Monday, December 15th. Wall Street Zen lowered Natera from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Natera in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $253.47.

Institutional Investors Weigh In On Natera

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Horizon Investments LLC increased its position in Natera by 22.0% in the 4th quarter. Horizon Investments LLC now owns 244 shares of the medical research company’s stock valued at $56,000 after acquiring an additional 44 shares during the period. Sound Income Strategies LLC lifted its position in Natera by 20.0% during the 4th quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock worth $62,000 after acquiring an additional 45 shares during the period. Savvy Advisors Inc. lifted its position in Natera by 3.1% during the 4th quarter. Savvy Advisors Inc. now owns 1,541 shares of the medical research company’s stock worth $353,000 after acquiring an additional 46 shares during the period. Siemens Fonds Invest GmbH grew its stake in shares of Natera by 3.1% in the 3rd quarter. Siemens Fonds Invest GmbH now owns 1,804 shares of the medical research company’s stock valued at $290,000 after purchasing an additional 54 shares during the last quarter. Finally, Alamea Verwaltungs GmbH increased its holdings in shares of Natera by 2.9% in the fourth quarter. Alamea Verwaltungs GmbH now owns 2,229 shares of the medical research company’s stock valued at $515,000 after purchasing an additional 62 shares during the period. 99.90% of the stock is owned by hedge funds and other institutional investors.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.